Ziltivekimab clinical trials
Also written COR-001.
How each study uses ziltivekimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ziltivekimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 2
Novo Nordisk A/S (11) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · University of Colorado, Denver (1) · ECRI bv (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test ziltivekimab, phase 3 first.
- Jan 2027ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackPhase 3 · Novo Nordisk A/S
Studies
Open first, then newest update. How each study uses ziltivekimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial InfarctionRecruitingPhase 3ECRI bvNCT07276282Written as Ziltivekimab
- A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart AttackRecruitingPhase 3Novo Nordisk A/SNCT07301034Written as Ziltivekimab
- Specifying the Anti-inflammatory Effects of ZiltivekimabCompletedPhase 3Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT06263244Written as Ziltivekimab
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationActive, not recruitingPhase 3Novo Nordisk A/SNCT06200207Written as Ziltivekimab
- A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationTerminatedPhase 3Novo Nordisk A/SNCT05636176Written as Ziltivekimab
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationCompletedPhase 3Novo Nordisk A/SNCT05021835Written as Ziltivekimab B
- ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackActive, not recruitingPhase 3Novo Nordisk A/SNCT06118281Written as Ziltivekimab
- Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.CompletedPhase 2Novo Nordisk A/SNCT04626505Written as Ziltivekimab
- A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and InflammationCompletedPhase 1Novo Nordisk A/SNCT05379829Written as Ziltivekimab
- Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 InhibitionCompletedPhase 2Novo Nordisk A/SNCT03926117Written as Ziltivekimab
- A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine ZiltivekimabCompletedPhase 1Novo Nordisk A/SNCT05721989Written as Ziltivekimab B
- Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001CompletedPhase 1/2Novo Nordisk A/SNCT02868229Written as COR-001
- Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis PatientsTerminatedPhase 1Novo Nordisk A/SNCT01559103Written as MEDI5117
- A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001CompletedPhase 1University of Colorado, DenverNCT03126318Written as COR-001
Codes
What other systems call ziltivekimab · ClinicalTrials.gg INT001659
- MeSH (NLM) C000718191ziltivekimabOne source ClinicalTrials.gov
- UNII (FDA) AN3Y2B4SX4ZILTIVEKIMABOne source FDA
- NCI Thesaurus C171844ZiltivekimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718191 | ziltivekimab | One source ClinicalTrials.gov |
| UNII (FDA) | AN3Y2B4SX4 | ZILTIVEKIMAB | One source FDA |
| NCI Thesaurus | C171844 | Ziltivekimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.